Clinical Trials Logo

Severe Pre-eclampsia clinical trials

View clinical trials related to Severe Pre-eclampsia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06385600 Not yet recruiting - Clinical trials for Severe Pre-eclampsia

Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The only effective treatment of severe preeclampsia is delivery of the fetus but immediate antihypertensive treatment is given to stabilize the patient and prevent further complications. All antihypertensive medication can potentially cross the placenta. At this time, there are no randomized control trials to base a recommendation for the use of one antihypertensive agent over another. However, certain medications are effective in lowering blood pressure with an acceptable safety profile in pregnancy. The choice of therapy depends on the acuity and severity of hypertension

NCT ID: NCT02314286 Not yet recruiting - Clinical trials for Severe Pre-eclampsia

Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective randomized single blind trial. Study population are women diagnosed with severe pre-eclampsia during singleton pregnancy, between 24+0 weeks and 41+6 weeks gestational age. The purpose of the study is to evaluate the effect of Rosuvastatin on the severe preeclampsia resolution at 48 hours after delivery. After screening and signing an informed consent form, before entering delivery room, a randomization 1:1 will be carried. 50 women will be in the treatment arm while 50 will be in the control arm. Both groups will be treated according to ACOG (The American College of Obstetricians and Gynecologists has the following clinical guidelines related to deliveries before 39 weeks) guidelines. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.